Evoq Remedies Ltd (EVOQ) Fair Value & Analysis

Healthcare · IN · Market cap ₹42.6M

Below-average quality, and trading another 43% above our fair value.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case (₹1.53). The favourable scenario is already priced in.
• Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (₹0.8107 to ₹1.53) leaves room in how you read the outcome.

Price vs Fair Value (4 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 25, 2026.

How to read this chart

53‑month range ₹1.70 – ₹23.75 · fair‑value band ₹0.8107 – ₹1.53 · the ₹1.76 price screens above the ₹1.23 fair value. Dashed = 300-day average. As of Aug 25, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Evoq Remedies Ltd (EVOQ) currently trades at ₹1.76, while our model-based Fair Value estimate is ₹1.23, implying the stock looks roughly 30.2% overvalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Evoq Remedies Ltd generated revenue of ₹268M at a net margin of -0.9%. It earns a return on equity of -0.5%. Fundamentals as of Aug 25, 2026

Our scenario range runs from ₹0.8107 (bear case) to ₹1.53 (bull case); at ₹1.76, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 71% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -7% fair-value upside, at -30%, EVOQ screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Evoq Remedies Limited engages in the marketing, trading, and distribution of pharmaceutical formulations in India. The company trades in sweeteners, such as acesulfame potassium, aspartem, dextrose, erythritol, euro vanillin powder, malodextrin, miglitol, etc.; amino acids, such as L- alanine, L-arginine, L-aspartic acid, L-carnitine, L-cystine, L-glutamic …

Full company description

Evoq Remedies Limited engages in the marketing, trading, and distribution of pharmaceutical formulations in India. The company trades in sweeteners, such as acesulfame potassium, aspartem, dextrose, erythritol, euro vanillin powder, malodextrin, miglitol, etc.; amino acids, such as L- alanine, L-arginine, L-aspartic acid, L-carnitine, L-cystine, L-glutamic acids, L-glutamine, L-glutathione, L-glycine, L-isoleucine, LL-trytophan, L-tyrosine, L-lysine, N-acetyl, and L-andystine; excipients, which include aspartem, bronopol, cross carmellous sodium, cross povidone, ethyl olliate, hard peraffin, hpmc all grades, light liquid paraffin, mannitol, menthol crystal, etc.; neutraceuticals; and opthalamics, which include atropine sulphate, bimatoprost, brimonidine, bromfenac, cyclopentolate, dorzolamide fluoromethelone, flurbiprofen, gatifloxacin, ketorolac tromethamine, latanoprost, natamycin, nepafenac, olopatadine, sulphacetamide sodium, timolol meleate, etc. It also offers ointments, such as adapalene, allantoin, avobenzone, azealic acid, calamine, chlorocresol, cetrimide, clindamycin phoshphate, clobetasol propionate, clotrimazole, cream base, cyclosporine, fluocinolol acetonide, fusidic acid, gamabenzene, gentamycin sulphate, halobetasol, hydroquinone, etc.; and oncology drugs, such as abiraterone acetate, alfuzosin, anastrazole, axitinib, azacitidine, bicalutamide, bleomycin, bosutinib, busualphan, capcitabine, carboplatin, cisplatin, etc. It also offers anti-biotic drugs, anti-malarial drugs, anti-allergic, anti cold drugs, analgesic/ anti-pyretic, anti inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastro intestinal drugs, steroids, gynecology drugs, calcium, multivitamins, anti-oxidants, and injections. In addition, it provides vitamins, dairy and spice products, sterile, active pharmaceutical ingredients, and veterinary feed products. The company was incorporated in 2010 and is based in Ahmedabad, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Evoq Remedies Ltd reported revenue of ₹255M in FY2026 versus ₹168M in FY2022, a compound +11.0%/yr. Reported net income was −₹2.4M in FY2026.

EVOQ screens 30% overvalued. Compare with McKesson Corporation →

Peer Group

Medical Distribution · 80 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 25, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.